24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
REGOLIEVA 40MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | REGOLIEVA 40MG |
|---|---|
| Composition | Regorafenib Tablet BP 40mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | Pack of 28 Tablets |
| Country of Origin | India |
REGOLIEVA 40MG (Regorafenib Tablet BP 40mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
REGOLIEVA 40 MG (Regorafenib Tablets BP 40 mg) is a prescription anticancer medicine containing Regorafenib 40 mg, an oral multi-kinase inhibitor used in the treatment of certain advanced cancers. Regorafenib belongs to a class of medicines known as Targeted Therapy Agents, which work by blocking multiple protein kinases involved in tumor growth, cancer progression, and blood vessel formation.
Regorafenib inhibits various signaling pathways responsible for cancer cell proliferation and angiogenesis (formation of new blood vessels that supply tumors). By targeting these pathways, the medicine helps slow tumor growth and disease progression.
REGOLIEVA 40 MG is commonly prescribed for the treatment of metastatic colorectal cancer (mCRC), gastrointestinal stromal tumors (GIST) after failure of prior therapies, and hepatocellular carcinoma (HCC) in selected patients. It may also be used according to the oncologist's recommendation as part of specific cancer treatment protocols.
The medicine is administered orally and should be taken exactly as prescribed by a qualified healthcare professional experienced in oncology treatment.
REGOLIEVA 40 MG is commonly used for:
Manufactured according to stringent pharmaceutical quality standards, REGOLIEVA 40 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Regorafenib therapy require regular monitoring of liver function, blood pressure, and overall health status throughout treatment.
Due to its targeted mechanism of action and proven clinical efficacy, REGOLIEVA 40 MG remains an important option in modern oncology care.
REGOLIEVA 40 MG (Regorafenib Tablets BP 40 mg) is primarily used in the treatment and management of certain advanced cancers.
Regorafenib is used in patients with colorectal cancer that has spread to other parts of the body after previous treatments.
The medicine is prescribed for GIST patients whose disease has progressed despite prior therapies.
Regorafenib may be used in selected patients with liver cancer following prior treatment.
Doctors may prescribe the medicine as part of advanced cancer treatment strategies.
The medicine helps block pathways involved in cancer growth and spread.
It is incorporated into internationally recognized oncology treatment guidelines.
Treatment may help slow disease progression and support improved clinical outcomes.
Regorafenib belongs to a class of medicines known as Multi-Kinase Inhibitors.
REGOLIEVA works by:
This targeted mechanism helps manage advanced cancers and supports effective disease control.
Like all medicines, REGOLIEVA 40 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Weakness and tiredness are commonly reported.
Redness, pain, swelling, or peeling of the palms and soles may occur.
Digestive disturbances are common during treatment.
Blood pressure may increase and require monitoring.
Reduced appetite may affect nutritional intake.
Some patients may experience unintended weight loss.
Changes in voice quality may occur.
Digestive discomfort may develop during therapy.
Mild to moderate skin reactions may occur.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of REGOLIEVA 40 MG (Regorafenib Tablets BP 40 mg) should always be determined by a qualified oncologist.
Treatment recommendations vary according to the disease being treated.
Prior therapies may influence treatment planning.
Hepatic function is an important consideration during therapy.
Dose adjustments may be required depending on side effects.
The patient's health status helps guide dosage decisions.
Before starting treatment, inform your doctor if you have:
Patients receiving Regorafenib therapy may require:
Patients should also disclose all prescription medicines, supplements, vitamins, and herbal products they are taking to avoid potential drug interactions.
Pregnant and breastfeeding women should not use this medicine unless specifically advised by a healthcare professional.
It is primarily used for metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (HCC).
Regorafenib is a targeted therapy medicine that blocks multiple protein kinases involved in cancer growth and blood vessel formation.
No. It is a targeted therapy medicine, not a traditional chemotherapy drug.
It blocks cancer growth pathways and inhibits tumor blood vessel formation, helping slow disease progression.
Yes. High blood pressure is a known side effect and requires regular monitoring.
Yes. Liver function monitoring is important during treatment.
Yes. Routine blood tests and clinical evaluations are essential throughout treatment.
Yes. This medicine should only be used under the guidance of a qualified oncologist.